INTRODUCTION

Multidrug-resistant (MDR) tuberculosis (TB) is caused
by Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampicin, the 2 most important anti-TB drugs and, therefore, is more difficult and expensive to treat than drug-susceptible TB. Although initiation of antiretroviral therapy (ART) during treatment for drug-susceptible TB significantly improves survival, few studies have described treatment outcomes among HIV-infected patients in MDR-TB treatment programs after widespread expansion of ART. [1] [2] [3] A recent systematic review found an overall 56.9% treatment success and 38% mortality among HIV-infected adults with MDR-TB. 4 However, most of the studies included in the review were conducted before widespread access to ART. 4 The objective of the present study is to describe treatment outcomes among HIV-infected and HIVuninfected MDR-TB patients after the expansion of the ART program in Botswana, using routinely collected MDR-TB program data. We hypothesized that high rates of treatment success can be achieved among HIV-infected MDR-TB patients, particularly among those that do not have advanced immune suppression at initial diagnosis.
METHODS
Study Population and Program Description
The study population was previously described in a paper based on an earlier version of the study database. 5 All patients enrolled in the national MDR-TB program were registered into a patient cohort database starting from 2006. For this study, we included data from adult and adolescent patients (age $15 years) diagnosed with confirmed or presumed MDR-TB. Patients with unknown HIV status, those who never started treatment, and those still on treatment at the time of the analysis were excluded.
During the study period (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) , patients diagnosed with MDR-TB in Botswana were referred to one of 5 specialized MDR-TB clinics across the country. 5 Multidrugresistant-tuberculosis clinics were staffed by physicians, nurses, and nursing assistants trained and supervised by one of the co-authors (C.M.). At each clinic, a designated TB focal person provided comprehensive counseling to patients regarding the MDR-TB treatment and its adverse effects, infection control, and the importance of treatment adherence. The clinic physician was responsible for initiating the MDR-TB treatment, monthly monitoring of adverse effects, and monitoring of sputum results. The MDR-TB nurse provided individual follow-up of each patient, including phone calls to patients who missed their monthly consultation. Patients were initiated on a standardized regimen of amikacin, levofloxacin, ethionamide, cycloserine, and pyrazinamide, for a minimum of 18 months after culture conversion. 5 The treatment was ambulatory with the exception of the extensively drugresistant (XDR)-TB cases, patients living with children less than 5 years old, and those sharing a room with other household members. These patients were treated as inpatients in the MDR-TB wards until they had culture converted. The treatment was administered daily under directly observed therapy at the nearest clinic to the patient's residence. Audiologists and social workers also worked closely with the physician and MDR-TB nurse to provide psychosocial support and hearing aids, if needed. Although no monetary incentives were provided, treatment support was provided through monthly food distribution and transportation to the MDR-TB clinic. At completion of treatment, patients continued to be followed up at the MDR-TB clinic to assess for relapse every quarter for 2 years.
Laboratory Procedures
Drug susceptibility testing (DST) for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, and streptomycin) was performed using the proportional agar method on Lowenstein-Jensen medium or the Mycobacteria Grow Indicator Tube 960 (Becton Dickinson Microbiology Systems, Sparks, MD). 6 Drug susceptibility testing for second-line drugs (fluoroquinolones, ethionaminde, kanamycin, amikacin, and capreomycin) was performed for patients who remained culture positive after 6 months of treatment. 7 HIV testing was done at the clinics on an optout basis using rapid HIV diagnostic tests. 8 
Measures
Treatment outcome was defined based on the 2008 World Health Organization (WHO) guidelines. 9 Patients who were cured or completed treatment were categorized as having achieved treatment success. Treatment failure was defined as having 2 or more positive cultures during the final 12 months of treatment, having a positive culture on any one of the final 3 cultures, or clinical decision to stop treatment for any reason. Any patient whose treatment was interrupted for 2 or more consecutive months was considered lost to follow-up. Death was defined as having died during treatment due to any cause.
We extracted HIV infection status and CD4 + T-cell values closest to MDR-TB treatment initiation from the cohort database. CD4 + T-cell counts were categorized as ,100, 100-199, 200-349, and $350 cells/mm 3 . Patients with second-line drug resistance patterns available at baseline were categorized as MDR-TB only, pre-XDR-TB [MDR-TB plus resistance to $1 second-line injectable drug (amikacin, capreomycin or kanamycin) or $1 fluoroquinolone], and XDR-TB (MDR-TB plus resistance to $1 second-line injectable drug and $1 fluoroquinolone).
Statistical Analysis
Bivariate comparisons were performed using the x 2 test or the Fisher's exact test, and continuous variables were compared using the Wilcoxon Rank Sum test. Two variables for treatment outcome were examined: (1) treatment success, defined as cure or complete (vs. death, failure, or lost to follow-up); and (2) death (vs. all other outcomes). Probabilities of treatment success and death were estimated using frequencies, and the 95% confidence intervals (95% CI) were estimated using the Score method. 10 Dose-response relationship between CD4 + T-cell count categories and treatment success or death was assessed using the x 2 test for trend. 10 We constructed multivariable Poisson regression models with robust variance to estimate the association between HIV-related immunosuppression and treatment outcomes while controlling for confounding variables. [11] [12] [13] [14] This method allowed us to estimate risk ratios, instead of logistic regression models, which generate odds ratio estimates. [11] [12] [13] [14] Separate models were constructed for treatment success and death as dependent variables. The primary independent variable was HIV-associated immune suppression, which was created by combining HIV infection status with CD4 + T-cell count categories. We used this combined variable to compare the probability of outcome in each CD4 + T-cell count category with that among HIV-uninfected patients. Patients with unknown CD4 + T-cell counts were excluded from the bivariate and multivariable analysis. We included the following covariates into the model as potential confounders based on a pre-specified conceptual framework of the causal relationship between HIV-associated immune suppression and TB treatment outcomes: age, sex, and prior history of TB. Factors that could have been influenced by HIVassociated immune suppression, including weight and other comorbidities, were not considered as confounders, because controlling of such factors could introduce bias in effect estimates. 15, 16 Review Board. Informed consent was not obtained from participants as this study involved analysis of routine program data.
RESULTS
Patient Characteristics
During 2006-2013, 695 patients were diagnosed with MDR-TB and entered into the MDR-TB registry. Twelve patients had multiple episodes, resulting in 708 MDR-TB cases during the period. We excluded data for 43 patients aged ,15 years, 11 patients with unknown HIV status, and 53 patients with unknown outcome status (51 patients were still on treatment, one patient did not start treatment, and the outcome for one patient was missing) (Fig. 1 ). Of the remaining 588 patients included in this analysis, 322 (54.9%) were male and the median age was 36 years [interquartile range (IQR), 29-47 years] ( Table 1) . Most of the patients had bacteriologically confirmed pulmonary MDR-TB and a prior history of TB treatment. Among 194 patients who had available second-line DST results, 47 (24.2%) were diagnosed with pre-XDR-TB and 9 (4.6%) were diagnosed with XDR-TB.
Overall, 440 (74.8%) patients achieved treatment success and 118 (20.1%) died. Treatment outcomes for 9 patients who had initially failed MDR-TB treatment were categorized as completed (n = 1), cured (n = 5), or death (n = 4) based on their subsequent treatment outcome. Of the patients diagnosed with pre-XDR-TB, 32 (68.1%) achieved treatment success and 13 (27.7%) died. Of the patients diagnosed with XDR-TB, 5 (55.6%) achieved treatment success and 3 (33.3%) died.
Our study population included 408 (69.4%) HIVinfected patients. Of these, 208 (51.0%) patients were on ART before starting MDR-TB treatment and 351 (86.0%) received ART during MDR-TB treatment (Table 1) . Of the 260 patients with known ART regimen, 236 (90.8%) were on first line ART regimens. The median CD4 + T-cell count at baseline was 234 cells/mm 3 (IQR, 124-379 cells/mm 3 ).
Among HIV-infected patients with known CD4 + T-cell counts, 17.9%, 24.0%, 28.8%, and 29.2% had CD4 + T-cell counts ,100, 100-199, 200-349, and $350 cells/mm 3 , respectively. HIV-infected MDR-TB patients were older (median age of 37 years vs. 32 years for HIV-uninfected patients; P = 0.019) and less likely to have previous history of TB treatment (P = 0.039). None of the other characteristics we examined differed between HIV-infected and HIVuninfected MDR-TB patients.
HIV-Associated Immune Suppression and Treatment Success
In bivariate analysis, the observed probability of treatment success was higher among HIV-uninfected patients compared with HIV-infected patients, but this difference was not statistically significant (79.4% vs. 73.0%; P = 0.121) ( Fig.  2A) . Likewise, no statistically significant differences were found when treatment success rates were compared between HIV-infected patients in the CD4 + T-cell categories (,100, 100-199, 200-349, $350 cells/mm 3 ) and HIV-uninfected patients (Table 2 ). However, we found evidence of an increasing trend in the probability of treatment success with increasing CD4 + T-cell count categories (from 64.6% among ,100 cells/mm 3 to 85.9% among $350 cells/mm 3 ; P trend = 0.002) ( Table 2 and Fig. 2A ). In addition, we observed lower probability of treatment success among patients who were male (70.8% vs. 80.0% among female patients; RR = 0.885; 95% CI: = 0.807 to 0.971), aged 45-54 years (69.0% vs. 83.3% among patients aged 15-24 years; RR = 0.828; 95% CI: = 0.709 to 0.966), and patients with previous history of TB treatment (74.2% vs. 92.0% among patients with no previous history of TB treatment; RR = 0.807; 95% CI: = 0.712 to 0.915) ( Table 2) .
In the multivariable model, no statistically significant differences were found in treatment success probabilities among HIV-infected patients in the CD4 + T-cell count categories compared with HIV-uninfected patients after controlling for sex, age, and prior history of TB treatment (Table 2) . Age was the only variable that remained independently associated with treatment success in the model [+10 years; risk ratio (RR) = 0.945; 95% CI: = 0.907 to 0.985].
HIV-Associated Immune Suppression and Death
In bivariate analysis, the observed probability of death was higher among HIV-infected patients compared with HIVuninfected patients, but this difference was not statistically significant (22.1% vs. 15.6%; P = 0.089) (Fig. 2B) . HIVinfected patients with CD4 + T-cell counts ,100 (RR = 2.009; 95% CI: = 1.170 to 3.448) and 100-199 cells/mm 3 (RR = 1.708; 95% CI: = 1.004 to 2.904) were more likely to die during treatment compared with HIV-uninfected patients (Table 3) . We found evidence of a decreasing trend in the probability of death with increasing CD4 + T-cell count categories (from 31.2% among ,100 cells/mm 3 to 12.8% among $ 350 cells/mm 3 ; P trend = 0.005) ( Table 3 and Fig.  2B ). In addition, we observed higher risk of death among patients who were male (24.5% vs. 14.7% among female patients; RR = 1.667; 95% CI: = 1.178 to 2.360) and aged 45-54 years (29.3% vs. 14.3% among patients aged 15-24 years; RR = 2.052; 95% CI: = 1.131 to 3.721) ( Table 3) . ║Amikacin-Levofloxacin-ethionamide-cycloserine-pyrazinamide + other secondline drugs.
¶CD4 + T-cell counts were unknown for 141 patients. #First line ART regimens were primarily: Tenofovir-Emtricitabine-Nevirapine, Zidovudine-Lamivudine-Efaviranz, Tenofovir-Emtricitabine-Efaviranz, or ZidovudineLamivudine-Nevirapine.
ART, antiretroviral therapy; IQR, interquartile range; TB, tuberculosis.
In the multivariable model, HIV-infected patients with CD4 + T-cell counts ,100 cells/mm 3 had higher risk of death compared with HIV-uninfected patients (RR = 1.890; 95% CI: = 1.098 to 3.254), after controlling for sex, age, and prior history of TB treatment (Table 3) . No statistically significant differences were found in risk of death between HIVuninfected patients and HIV-infected patients in CD4 + T-cell categories $ 100 cells/mm 3 (Table 3 ). Male sex (vs. female; RR = 1.630; 95% CI: = 1.041 to 2.553) and older age (+10 years; RR = 1.228; 95% CI: = 1.072 to 1.406) were also independently associated with death.
DISCUSSION
We found high treatment success rates among patients managed by the national MDR-TB program in Botswana. Aspects of this program that may have contributed to high success rates include pre-initiation counseling, strict directly observed therapy, food and transport incentives, and followup of patients who miss their monthly consultations. In this setting, we found similar probabilities of treatment success and death between HIV-uninfected MDR-TB patients and HIV-infected MDR-TB patients in CD4 + T-cell categories $100 cells/mm 3 . Notably, the WHO goal of 75% treatment success for MDR-TB was reached for HIV-uninfected patients and HIV-infected patients with CD4 + T-cell count $200 cells/mm 3 (Table 2 and Fig. 2A) . However, HIVinfected MDR-TB patients with advanced immune suppression (CD4 + T-cell count , 100 cells/mm 3 ) were more likely to die during treatment compared with HIV-uninfected patients. Thus, our data suggest that, in the ART era, high rates of treatment success can be achieved for HIV-infected MDR-TB patients who have not progressed to an advanced stage of immune suppression.
Our findings are consistent with a recent systematic review, which suggests that similar levels of treatment success can be achieved between HIV-infected and HIVuninfected MDR-TB patients. 4 However, the 73.0% treatment success among HIV-infected MDR-TB patients in our study is substantially higher than the 56.9% reported in that systematic review. 4 The difference in treatment success might be largely due to inclusion in the systematic review of studies done before ART access. 4 Our findings are similar to a recent study in Haiti that reported a 78% treatment success among HIV-infected MDR-TB patients on ART. 17 That study was limited by a small sample size (N = 110), including only 27 HIV-infected MDR-TB patients. 17 Using information from a large national cohort of MDR-TB patients, we confirm and extend the findings from the Haiti study by showing that similar levels of treatment success can be achieved among HIV-uninfected MDR-TB patients and HIV-infected MDR-TB patients with CD4 + T-cell count $200 cells/mm 3 , in the context of concomitant ART availability in a well-managed MDR-TB program.
Treatment success among HIV-uninfected patients in our study was lower than the 84%-89% treatment success reported for the short-course MDR-TB regimen recently endorsed by the WHO. [18] [19] [20] [21] Additional research is needed to determine the effectiveness of the WHO-endorsed shortcourse therapy in Botswana, particularly for HIV-infected patients who comprise nearly 70% of the diagnosed MDR-TB patients.
Although Botswana's MDR-TB treatment program achieved successful outcomes and very low rates of treatment failure and loss to follow-up, mortality remained unacceptably high among HIV-infected patients with baseline CD4 + T-cell counts ,100 cells/mm 3 . Among HIV-infected patients with known CD4 + T-cell counts, nearly 20% had ,100 cells/mm 3 at the time of MDR-TB treatment initiation. These findings highlight the importance of reaching all HIV-infected persons with ART as part of comprehensive HIV care to prevent advanced immunosuppression and reduce mortality from MDR-TB and other causes. Although intensified public health efforts have significantly increased ART coverage in Botswana, our study suggests that gaps in coverage continue to adversely affect HIV-related mortality. 22, 23 In June 2016, Botswana launched a "test and treat" program, designed to administer ART to all patients diagnosed with HIV. Based on our findings, this new program could improve treatment outcomes for HIVinfected patients who develop MDR-TB. Additional research is needed to improve the clinical management of MDR-TB patients with advanced immunosuppression. 24 Strengths of our study include the use of programmatic data that reflect "real-life" experience of the MDR-TB program and its patients. In addition, our sample size of nearly 600 patients, including 408 HIV-infected patients allowed us to make comparisons between HIV-uninfected patients and HIVinfected patients stratified by CD4 + T-cell counts. Our study should be interpreted with consideration of the following limitations. First, we did not collect information on the cause of death. HIV-infected persons with CD4 T-cell counts ,100 cells/mm 3 are at high risk of death caused by numerous etiologies other than TB, including cryptococcal meningitis and other opportunistic infections. 25 However, ascertaining the cause of death for patients with multiple comorbidities is challenging, and we used the WHO definition of defining death as death due to any cause during TB treatment. 9 Of note, we classified outcomes based on the patient's latest MDR-TB treatment episode, which partially explains the low failure rate in our study. It is also possible that more patients who died were patients who initially failed treatment. However, given the program's strong emphasis on individual patient follow-up, such "missed" failure events are likely to be minimal. Another limitation is that the program database did not include detailed HIV-related treatment variables, including ART failure and interruption, which could have affected MDR-TB treatment outcomes.
Drug susceptibility testing for second-line drugs was not done for all MDR-TB patients. Therefore, our study could have underestimated the proportion of patients identified as having pre-XDR and XDR-TB. Similarly, we did not perform DST for pyrazinamide resistance and, as the latest national drug resistance survey did not systematically test for pyrazinamide resistance, we do not know its background prevalence. 26 During the study period, molecular diagnostics, such as Xpert MTB/RIF and line probe assays, were not routinely used. Recently, the Botswana Ministry of Health recommended replacing smear microscopy with Xpert MTB/ RIF as the primary TB diagnostic tool. This policy change could lead to earlier diagnosis and more complete ascertainment of MDR-TB cases in Botswana.
CONCLUSIONS
We report treatment outcomes from a large national cohort of MDR-TB patients with access to ART in Botswana. High rates of treatment success are possible for HIV-infected MDR-TB patients with moderate to high immune function. Based on our findings, we recommend improved efforts to prevent advanced immunosuppression among HIV-infected persons and additional research to reduce mortality among MDR-TB patients with advanced HIV-associated immunosuppression.
